NSB to investigate treatment for post-COVID Fibrosis
Filed with ASX · · 3 pages · English
• Neuroscientific Biopharmaceuticals (NSB) is partnering with The Institute of Respiratory Health and The University of Western Australia to test the effectiveness of EmtinB and other Metallothionein derived peptides (EmtinAc, EmtinAn, EmtinBn) as potential therapy for long term respiratory complications of Covid-19. • With the number of COVID cases exceeding 50 million since December 2019 and ris
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- Strategic Placement to AlphaSwiss Partners
- Appendix 4E and Annual Report
- Updated Appendix 4C
- Full Report from Multiple Sclerosis Study
- EmtinB Positive Results in MS
Later from Neuroscientific Biopharmaceuticals
- Key Executive Appointments to Support Clinical Studies
- Manufacturing Update
- Appendix 4C - quarterly
- Update on Pivotal Ocular Safety Studies
- R&D Tax Rebate Received
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals